Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14573386rdf:typepubmed:Citationlld:pubmed
pubmed-article:14573386lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:14573386lifeskim:mentionsumls-concept:C0521119lld:lifeskim
pubmed-article:14573386lifeskim:mentionsumls-concept:C0596902lld:lifeskim
pubmed-article:14573386lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:14573386lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:14573386lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:14573386lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:14573386lifeskim:mentionsumls-concept:C1554184lld:lifeskim
pubmed-article:14573386lifeskim:mentionsumls-concept:C0599682lld:lifeskim
pubmed-article:14573386pubmed:issue7lld:pubmed
pubmed-article:14573386pubmed:dateCreated2003-10-23lld:pubmed
pubmed-article:14573386pubmed:abstractTextCompounds that block both serotonin (5-HT) and norepinephrine (NE) transporters have been proposed to have improved antidepressant efficacy. We compared the ability of four dual transporter inhibitors-chlorimipramine, duloxetine, milnacipran and venlafaxine-to block monoamine transporters in vitro and in vivo and increase extracellular monoamines in rat brain. Inhibition of radioligand binding to clonal human monoamine transporters in vitro and in vivo in rats was determined. Extracellular concentrations of 5-HT and NE in rat prefrontal cortex (PFC) were quantified using the microdialysis technique. All compounds blocked binding to human 5-HT and NE transporters, although chlorimipramine and venlafaxine had markedly greater affinity for 5-HT than NE transporters. In vivo, chlorimipramine and duloxetine potently blocked both transporters, milnacipran blocked both with lower potency and venlafaxine only blocked the 5-HT transporter. Chlorimipramine and duloxetine increased robustly and approximately equally monoamine extracellular concentrations. Milnacipran produced only small increases in NE, whereas venlafaxine increased 5-HT markedly at the lower doses and both monoamines at high doses. Thus, the dual transporter inhibitors blocked 5-HT and NE transporters in vitro and in vivo with varying potency. Chlorimipramine, duloxetine, and high dose venlafaxine acted as dual transporter inhibitors in rat PFC and increased extracellular concentrations of the monoamines, indicating functional dual transporter inhibition.lld:pubmed
pubmed-article:14573386pubmed:languageenglld:pubmed
pubmed-article:14573386pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14573386pubmed:citationSubsetIMlld:pubmed
pubmed-article:14573386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14573386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14573386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14573386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14573386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14573386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14573386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14573386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14573386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14573386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14573386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14573386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14573386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14573386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14573386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14573386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14573386pubmed:statusMEDLINElld:pubmed
pubmed-article:14573386pubmed:monthDeclld:pubmed
pubmed-article:14573386pubmed:issn0028-3908lld:pubmed
pubmed-article:14573386pubmed:authorpubmed-author:Hemrick-Lueck...lld:pubmed
pubmed-article:14573386pubmed:authorpubmed-author:EvansDavid...lld:pubmed
pubmed-article:14573386pubmed:authorpubmed-author:PerryKenneth...lld:pubmed
pubmed-article:14573386pubmed:authorpubmed-author:NelsonDavid...lld:pubmed
pubmed-article:14573386pubmed:authorpubmed-author:BymasterFrank...lld:pubmed
pubmed-article:14573386pubmed:authorpubmed-author:ThrelkeldPenn...lld:pubmed
pubmed-article:14573386pubmed:authorpubmed-author:KochSusanneSlld:pubmed
pubmed-article:14573386pubmed:authorpubmed-author:ThompsonLinda...lld:pubmed
pubmed-article:14573386pubmed:issnTypePrintlld:pubmed
pubmed-article:14573386pubmed:volume45lld:pubmed
pubmed-article:14573386pubmed:ownerNLMlld:pubmed
pubmed-article:14573386pubmed:authorsCompleteYlld:pubmed
pubmed-article:14573386pubmed:pagination935-44lld:pubmed
pubmed-article:14573386pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:meshHeadingpubmed-meshheading:14573386...lld:pubmed
pubmed-article:14573386pubmed:year2003lld:pubmed
pubmed-article:14573386pubmed:articleTitleComparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats.lld:pubmed
pubmed-article:14573386pubmed:affiliationLilly Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA.lld:pubmed
pubmed-article:14573386pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14573386pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:14573386pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14573386lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14573386lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14573386lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14573386lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14573386lld:pubmed